-transparent.png){kind=logo}
OBJECTIVE This study investigated the effect of dietary protein restriction on disease progression and how it is influenced by proteinuria in patients with type 2 diabetic nephropathy(DN) and renal failure. METHODS One hundred and six type 2 DN patients whose baseline creatinine clearance(Ccr) values were 29 +/- 12 ml/min/1.73 m2 were maintained on a diet containing 0.66 +/- 0.05 g/kg/day of protein. They were classified into 3 groups according to mean dietary protein intake(DPI) estimated from urinary urea nitrogen excretion during the follow-up period of 23 +/- 14 months(I, < 0.7 g/kg/day; II, 0.7-0.89 g/kg/day; III, > or = 0.9 g/kg/day). Furthermore, they were divided into 3 subgroups according to mean urinary protein excretion(UP) during the follow-up period (a, > or = 5.0 g/day; b, 2.0-4.99 g/day; c, < 2.0 g/day). Their rates of decline of Ccr(D-Ccr) and the changes in UP were examined. RESULTS There were no significant differences in D-Ccr among Group Ia, IIa, and IIIa(1.1 +/- 0.6, 1.5 +/- 0.7, 1.2 +/- 0.6 ml/min/1.73 m2/month), among Group Ib, IIb, and IIIb(0.6 +/- 0.3, 0.7 +/- 0.4, 0.8 +/- 0.4 ml/min/1.73 m2/month), and also among Group Ic, IIc, and IIIc(0.1 +/- 0.3, 0.2 +/- 0.2, 0.2 +/- 0.6 ml/min/1.73 m2/month). On the other hand, significant differences were revealed in D-Ccr among Group Ia, Ib, and Ic, among Group IIa, IIb, and IIc, and among Group IIIa, IIIb, and IIIc. There were no significant differences in final UP and minimum UP during follow-up among 3 groups of different DPI levels in patients with 5.0 g/day < or = baseline UP(n = 49) and in patients with 2.0 < or = baseline UP < 5.0 g/day(n = 37). However, significant correlations were demonstrated between D-Ccr and the relative changes in UP between baseline and minimum during the follow-up period in both patients(r = 0.49, 0.48, p < 0.001, p < 0.01). CONCLUSIONS Irrespective of the level of dietary protein restriction, proteinuria has a great influence on disease progression, and the reduction in UP correlates with retardation of renal function loss in patients with type 2 DN and renal failure.
T Okada, and
H Matsumoto, and
T Nakao, and
Y Nagaoka, and
T Shino, and
M Yoshino, and
H Hidaka, and
Y Kanazawa
December 1989,
Lancet (London, England),
T Okada, and
H Matsumoto, and
T Nakao, and
Y Nagaoka, and
T Shino, and
M Yoshino, and
H Hidaka, and
Y Kanazawa
March 1986,
The International journal of artificial organs,
T Okada, and
H Matsumoto, and
T Nakao, and
Y Nagaoka, and
T Shino, and
M Yoshino, and
H Hidaka, and
Y Kanazawa
January 1994,
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
T Okada, and
H Matsumoto, and
T Nakao, and
Y Nagaoka, and
T Shino, and
M Yoshino, and
H Hidaka, and
Y Kanazawa
August 1987,
Harefuah,
T Okada, and
H Matsumoto, and
T Nakao, and
Y Nagaoka, and
T Shino, and
M Yoshino, and
H Hidaka, and
Y Kanazawa
October 1982,
Kidney international,
T Okada, and
H Matsumoto, and
T Nakao, and
Y Nagaoka, and
T Shino, and
M Yoshino, and
H Hidaka, and
Y Kanazawa
November 1987,
The American journal of the medical sciences,
T Okada, and
H Matsumoto, and
T Nakao, and
Y Nagaoka, and
T Shino, and
M Yoshino, and
H Hidaka, and
Y Kanazawa
December 1991,
Journal of nutritional science and vitaminology,
T Okada, and
H Matsumoto, and
T Nakao, and
Y Nagaoka, and
T Shino, and
M Yoshino, and
H Hidaka, and
Y Kanazawa
April 1996,
Annals of internal medicine,
T Okada, and
H Matsumoto, and
T Nakao, and
Y Nagaoka, and
T Shino, and
M Yoshino, and
H Hidaka, and
Y Kanazawa
October 1990,
The American journal of medicine,
T Okada, and
H Matsumoto, and
T Nakao, and
Y Nagaoka, and
T Shino, and
M Yoshino, and
H Hidaka, and
Y Kanazawa
October 1987,
Kidney international. Supplement,
